Logo image of SAGE

SAGE THERAPEUTICS INC (SAGE) Stock Fundamental Analysis

NASDAQ:SAGE - Nasdaq - US78667J1088 - Common Stock - Currency: USD

7.31  +0.16 (+2.24%)

After market: 7.33 +0.02 (+0.27%)

Fundamental Rating

3

SAGE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. The financial health of SAGE is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SAGE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SAGE had negative earnings in the past year.
SAGE had a negative operating cash flow in the past year.
SAGE had negative earnings in 4 of the past 5 years.
In the past 5 years SAGE reported 4 times negative operating cash flow.
SAGE Yearly Net Income VS EBIT VS OCF VS FCFSAGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M -600M

1.2 Ratios

SAGE has a Return On Assets of -73.22%. This is in the lower half of the industry: SAGE underperforms 66.96% of its industry peers.
Looking at the Return On Equity, with a value of -86.15%, SAGE is in line with its industry, outperforming 50.09% of the companies in the same industry.
Industry RankSector Rank
ROA -73.22%
ROE -86.15%
ROIC N/A
ROA(3y)-57.96%
ROA(5y)-34.18%
ROE(3y)-65.47%
ROE(5y)-38.73%
ROIC(3y)N/A
ROIC(5y)N/A
SAGE Yearly ROA, ROE, ROICSAGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

SAGE has a Gross Margin of 77.10%. This is amongst the best in the industry. SAGE outperforms 85.97% of its industry peers.
In the last couple of years the Gross Margin of SAGE has declined.
The Profit Margin and Operating Margin are not available for SAGE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.74%
GM growth 5Y-3.93%
SAGE Yearly Profit, Operating, Gross MarginsSAGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

SAGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
SAGE has more shares outstanding than it did 1 year ago.
SAGE has more shares outstanding than it did 5 years ago.
SAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SAGE Yearly Shares OutstandingSAGE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SAGE Yearly Total Debt VS Total AssetsSAGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -5.78, we must say that SAGE is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.78, SAGE is doing worse than 64.83% of the companies in the same industry.
SAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.78
ROIC/WACCN/A
WACC9.44%
SAGE Yearly LT Debt VS Equity VS FCFSAGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 7.42 indicates that SAGE has no problem at all paying its short term obligations.
With a decent Current ratio value of 7.42, SAGE is doing good in the industry, outperforming 70.16% of the companies in the same industry.
A Quick Ratio of 7.42 indicates that SAGE has no problem at all paying its short term obligations.
SAGE has a better Quick ratio (7.42) than 70.16% of its industry peers.
Industry RankSector Rank
Current Ratio 7.42
Quick Ratio 7.42
SAGE Yearly Current Assets VS Current LiabilitesSAGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

6

3. Growth

3.1 Past

SAGE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.08%, which is quite impressive.
The Revenue for SAGE has decreased by -52.30% in the past year. This is quite bad
The Revenue has been growing by 42.99% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)36.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)-52.3%
Revenue growth 3Y87.07%
Revenue growth 5Y42.99%
Sales Q2Q%-83.56%

3.2 Future

SAGE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.93% yearly.
SAGE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 51.34% yearly.
EPS Next Y46.14%
EPS Next 2Y25.7%
EPS Next 3Y20.73%
EPS Next 5Y14.93%
Revenue Next Year95.12%
Revenue Next 2Y80.8%
Revenue Next 3Y51.64%
Revenue Next 5Y51.34%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SAGE Yearly Revenue VS EstimatesSAGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
SAGE Yearly EPS VS EstimatesSAGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SAGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SAGE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SAGE Price Earnings VS Forward Price EarningsSAGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SAGE Per share dataSAGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as SAGE's earnings are expected to grow with 20.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.7%
EPS Next 3Y20.73%

More info and screens

0

5. Dividend

5.1 Amount

SAGE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAGE THERAPEUTICS INC

NASDAQ:SAGE (2/21/2025, 8:00:01 PM)

After market: 7.33 +0.02 (+0.27%)

7.31

+0.16 (+2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11 2025-02-11/amc
Earnings (Next)04-23 2025-04-23/bmo
Inst Owners79.77%
Inst Owner Change-1.4%
Ins Owners0.34%
Ins Owner Change1.7%
Market Cap449.42M
Analysts68
Price Target8.09 (10.67%)
Short Float %7.7%
Short Ratio2.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.28%
Min EPS beat(2)-1.61%
Max EPS beat(2)2.18%
EPS beat(4)1
Avg EPS beat(4)-1.76%
Min EPS beat(4)-7.14%
Max EPS beat(4)2.18%
EPS beat(8)2
Avg EPS beat(8)-8.21%
EPS beat(12)4
Avg EPS beat(12)-5.53%
EPS beat(16)6
Avg EPS beat(16)-4.33%
Revenue beat(2)1
Avg Revenue beat(2)-2.63%
Min Revenue beat(2)-12.99%
Max Revenue beat(2)7.74%
Revenue beat(4)2
Avg Revenue beat(4)6.19%
Min Revenue beat(4)-12.99%
Max Revenue beat(4)34.14%
Revenue beat(8)4
Avg Revenue beat(8)3.04%
Revenue beat(12)6
Avg Revenue beat(12)0.42%
Revenue beat(16)6
Avg Revenue beat(16)-5.56%
PT rev (1m)-10.63%
PT rev (3m)-40.42%
EPS NQ rev (1m)22.32%
EPS NQ rev (3m)35.27%
EPS NY rev (1m)9.84%
EPS NY rev (3m)15.58%
Revenue NQ rev (1m)-10.38%
Revenue NQ rev (3m)-24.35%
Revenue NY rev (1m)-3.99%
Revenue NY rev (3m)-2.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.9
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-6.59
EYN/A
EPS(NY)-3.55
Fwd EYN/A
FCF(TTM)-4.35
FCFYN/A
OCF(TTM)-4.35
OCFYN/A
SpS0.67
BVpS7.56
TBVpS7.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.22%
ROE -86.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.1%
FCFM N/A
ROA(3y)-57.96%
ROA(5y)-34.18%
ROE(3y)-65.47%
ROE(5y)-38.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.74%
GM growth 5Y-3.93%
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.42
Quick Ratio 7.42
Altman-Z -5.78
F-Score2
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)40.51%
Cap/Depr(5y)28.52%
Cap/Sales(3y)4.11%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
EPS Next Y46.14%
EPS Next 2Y25.7%
EPS Next 3Y20.73%
EPS Next 5Y14.93%
Revenue 1Y (TTM)-52.3%
Revenue growth 3Y87.07%
Revenue growth 5Y42.99%
Sales Q2Q%-83.56%
Revenue Next Year95.12%
Revenue Next 2Y80.8%
Revenue Next 3Y51.64%
Revenue Next 5Y51.34%
EBIT growth 1Y24.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.65%
EBIT Next 3Y19.31%
EBIT Next 5Y16.48%
FCF growth 1Y50.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.57%
OCF growth 3YN/A
OCF growth 5YN/A